Skip to main content

Health economic modeling for medical technologies in Europe

Early and comprehensive economic models to determine economic value proposition and inform healthcare decision-makers

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Three more health apps obtained reimbursement in Germany

24 May 2023

Between late April and May 2023, three more health apps were introduced in the Directory of digital health applications (DiGAs) at the Federal Office for Drugs and Medical Devices (BfArM) and thus became reimbursable. These apps can be prescribed by physicians and psychotherapists and will be reimbursed by health insurers. In total, 47 health apps are currently available in the DiGA Directory, and six health apps were delisted from the Directory.

On April 21, 2023, "Selfapys Online-Kurs bei chronischen Schmerzen", developed by Selfapy GmbH, Germany, was introduced in the Directory. It is a digital application for patients suffering from chronic pain. The course imparts methods and techniques based on cognitive behavioral therapy and supports implementing and documenting the exercises intended to improve the user's symptoms. The online course for chronic pain can be used in the sense of multimodal pain therapy to accompany an existing treatment, to bridge the waiting time for therapy, and for stand-alone therapy with the digital health app. The app is available in German with a tariff of €540.

"NeuroNation MED", developed by Synaptikon GmbH, Germany, was introduced in the Directory on May 13, 2023. It is a mobile application for personalized cognitive training based on exercises of various cognitive functions (Multi-Domain Cognitive Training). "NeuroNation MED" aims to support patients in alleviating the symptoms of mild acquired or neurodegenerative cognitive impairment. The app offers two core elements: personalized cognitive training and health information. Cognitive training is adapted to the personal abilities and needs of the patients based on their performance in training and recurring evaluations. The health information provides data on brain health and animated instructions for mental and physical relaxation exercises. The effectiveness of the training plan is continuously optimized through interactions with the user. The app is available in German and English with a tariff of €499.

On May 15, 2023, "ProHerz", developed by ProCarement GmbH, Germany, was introduced in the Directory. "ProHerz" is a therapy companion for patients with heart failure to support self-management and as an early warning system to identify changes in the course of the disease. For this purpose, the vital signs measured daily by the patients (blood pressure, oxygen saturation, pulse, temperature, weight) are recorded in mobile devices (smartphone, tablet) and analyzed automatically. This makes it possible to document and monitor the state of health of patients independently. In addition, based on this data and the individual health and therapy profile, "ProHerz" offers digitally implemented and personalized health coaching and other risk prevention functions. The app is available in German with a range of tariffs of €495-€605.

The full details in German can be found here (Selfapys Online-Kurs bei chronischen Schmerzen), here (NeuroNation MED), and here (ProHerz).

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Contact us to get a free, three-month, no-obligation trial.